No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting.
BACKGROUND
There is a lack of data comparing the protease inhibitors (PIs) atazanavir (ATV) and darunavir (DRV) in a real-world setting. This study compared persistence (time to switch/discontinuation) to therapy between ATV-treated and DRV-treated patients with human immunodeficiency virus (HIV).


METHODS
Retrospective, observational cohort study using US insurance claims for commercially and Medicaid-insured patients. Patients were aged ≥18 years and initiated an ATV- or DRV-based regimen boosted with ritonavir between 7/1/2006 and 3/31/2013, with ≥6 months of continuous enrolment prior to and ≥3 months of continuous enrolment following initiation; patients were required to have ≥1 inpatient or outpatient medical claim with an ICD-9-CM diagnosis code for HIV during that time period of enrolment. Patients with no claims for antiretroviral therapy (ART) any time prior to initiation were considered to be ART-naïve. Time to switch/discontinuation was defined as the number of days from initiation of the regimen until earliest of: (1) a ≥30-day continuous gap in therapy in ATV or DRV; (2) a prescription claim for an ART agent that was not part of the initial regimen (with the exception of changes in concomitant nucleoside reverse transcriptase inhibitors or the addition of integrase inhibitors); (3) censoring at a ≥30-day continuous gap in therapy in ritonavir; (4) censoring at disenrolment from insurance benefits or (5) censoring at the study end date (9/30/2013 in the commercial data and 12/31/2013 in the Medicaid data). Time to switch/discontinuation was compared using incidence rates and multivariable Cox proportional hazards models adjusted for calendar time, patient demographics and clinical characteristics.


RESULTS
Table 1 displays the study results and cohort sample sizes. Mean ages across the cohorts were 41-42 years. The proportions of patients who were ART-naïve were 58-59% among the ATV/r cohorts and 53-55% among the DRV/r cohorts. There were no significant differences in the adjusted hazards of switch/discontinuation between the cohorts.


CONCLUSIONS
The incidence of switch/discontinuation was higher among Medicaid patients (who may be socioeconomically disadvantaged) than Commercial patients. There were no significant differences in persistence (time to switch/discontinuation) with the initiated PI among HIV patients who initiated an ATV-based regimen versus a DRV-based regimen.
Life Sciences, Truven Health Analytics, Cambridge, MA, USA.
Amanda M
AM
Farr
Life Sciences, Truven Health Analytics, Bethesda, MD, USA.
Stephen S
SS
Johnston
US Medical HIV, Bristol-Myers Squibb, Princeton, NJ, USA.
Corey
C
Ritchings
Life Sciences, Truven Health Analytics, Cambridge, MA, USA.
Matthew
M
Brouillette
Health Economics and Outcomes Research, Bristol-Myers Squibb, Plainsboro, NJ, USA.
Lisa
L
Rosenblatt